Early (18F) fluoro-2-deoxy-D-glucose positron emission tomography/computerized tomography (PET/CT) imaging as a tool for response assessment in T-cell non-Hodgkin’s lymphoma (TCL): An update to a phase II study of HCVIDD alternated with methotrexate (MTX) and cytarabine (Ara-C)

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 8538-8538
Author(s):  
J. L. Cultrera ◽  
R. F. Nunez ◽  
J. E. Romaguera ◽  
F. B. Hagemeister ◽  
M. A. Rodriguez ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
T Cell ◽  
Computerized Tomography ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Response Assessment ◽  
Ct Imaging ◽  
Emission Tomography ◽  
Positron Emission ◽  
Pet Ct

Etiology of Solitary Extrapulmonary Positron Emission Tomography and Computed Tomography Findings in Patients With Lung Cancer

2005 ◽  
Vol 23 (28) ◽  
pp. 6846-6853 ◽  
Author(s):  
Didier Lardinois ◽  
Walter Weder ◽  
Marina Roudas ◽  
Gustav K. von Schulthess ◽  
Michaela Tutic ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Positron Emission Tomography ◽  
Ct Imaging ◽  
Emission Tomography ◽  
Whole Body ◽  
Benign Tumors ◽  
Positron Emission ◽  
Pet Ct ◽  
The Impact

Purpose The aim of this prospective study was to assess the incidence and the nature of solitary extrapulmonary [18F] fluorodeoxyglucose (FDG) accumulations in patients with non–small-cell lung cancer (NSCLC) staged with integrated positron emission tomography and computed tomography (PET/CT) and to evaluate the impact on management. Patients and Methods A total of 350 patients with NSCLC underwent whole-body PET/CT imaging. All solitary extrapulmonary FDG accumulations were evaluated by histopathology, further imaging, or clinical follow-up. Results PET/CT imaging revealed extrapulmonary lesions in 110 patients. In 72 patients (21%), solitary lesions were present. A diagnosis was obtained in 69 of these patients, including 37 (54%) with solitary metastases and 32 (46%) with lesions unrelated to the lung primary. Histopathologic examinations of these 32 lesions revealed a second clinically unsuspected malignancy or a recurrence of a previous diagnosed carcinoma in six patients (19%) and a benign tumor or inflammatory lesion in 26 patients (81%). The six malignancies consisted of carcinoma of the breast in two patients, and carcinoma of the orbit, esophagus, prostate, and non-Hodgkin's lymphoma in one patient each. Benign tumors and inflammatory lesions included eight colon adenomas, four Warthin's tumors, one granuloma of the lower jaw, one adenoma of the thyroid gland, one compensatory muscle activity due to vocal chord palsy, two occurrences of arthritis, three occurrences of reflux esophagitis, two occurrences of pancreatitis, two occurrences of diverticulitis, one hemorrhoidal inflammation, and one rib fracture. Conclusion Solitary extrapulmonary FDG accumulations in patients with newly diagnosed lung cancer should be analyzed critically for correct staging and optimal therapy, given that up to half of the lesions may represent unrelated malignancies or benign disease.

Positron emission tomography for unexplained serum SCC-Ag elevation during follow-up in cervical cancer patients -A phase II study

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 9606-9606
Author(s):  
T.-C. Chang ◽  
T.-C. Yen ◽  
J.-H. Hong ◽  
C.-H. Lai ◽  
K.-K. Ng ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Positron Emission Tomography ◽  
Cancer Patients ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Emission Tomography ◽  
Positron Emission

Positron emission tomography for unexplained serum SCC-Ag elevation during follow-up in cervical cancer patients -A phase II study

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 9606-9606
Author(s):  
T.-C. Chang ◽  
T.-C. Yen ◽  
J.-H. Hong ◽  
C.-H. Lai ◽  
K.-K. Ng ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Positron Emission Tomography ◽  
Cancer Patients ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Emission Tomography ◽  
Positron Emission

scholarly journals The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome

2020 ◽  
Author(s):  
Kristina Noring ◽  
Mattias Carlsten ◽  
Kristina Sonnevi ◽  
Björn Wahlin
Keyword(s):  
Positron Emission Tomography ◽  
Stem Cell ◽  
T Cell ◽  
Stem Cell Transplantation ◽  
B Cell ◽  
Cell Lymphoma ◽  
Emission Tomography ◽  
Positron Emission ◽  
Pet Ct ◽  
Improved Outcome

Abstract Background Chimeric antigen-receptor T-cell and bispecific antibody therapies will likely necessitate a reconsideration of the role of autologous stem-cell transplantation (ASCT) in lymphoma. Patients who are likely to profit from ASCT need to be better identified. Methods Here, we investigated the value of positron emission tomography/computerized tomography (PET/CT) before ASCT. All 521 patients transplanted for lymphoma 1994–2019 at Karolinska (497 conditioned with BEAM) were included. Results Outcome improved over three calendar periods 1994–2004, 2005–2014, 2015–2019 (2-year overall survival [OS]: 66%, 73%, 83%; P = 0.018). Non-relapse mortality (NRM) at 100 days over the three periods were 9.8%, 3.9%, 2.9%, respectively. The OS improvement between 1994–2004 and 2005–2014 was due to lower NRM (P = 0.027), but the large OS advance from 2015 was not accompanied by a significant reduction in NRM (P = 0.6). The fraction of PET/CT as pre-ASCT assessment also increased over time: 1994–2004, 2%; 2005–2014, 24%; 2015–2019, 60% (P < 0.00005). Complete responses (PET/CT-CR) were observed in 77% and metabolically active partial responses (PET/CT-PR) in 23%. PET/CT-CR was a predictor for survival in the entire population (P = 0.0003), also in the subpopulations of aggressive B-cell (P = 0.004) and peripheral T-cell (P = 0.024) lymphomas. Two-year OS and progression-free survival (OS/PFS) for patients in PET/CT-CR were in relapsed/refractory aggressive B-cell lymphoma 87%/75% and peripheral T-cell lymphoma 91%/78%. The corresponding figures in PET/CT-PR were 43%/44% and 33%/33%. Patients with solitary PET/CT-positive lesions showed acceptable outcome with ASCT followed by local irradiation (2-year OS/PFS 80%/60%). CT was less discriminative: 2-year OS/PFS: CT-CR, 76%/66%; CT-PR, 62%/51%. Outcome was inferior after BEAC compared with BEAM conditioning. Conclusions We conclude that the improved outcome reflects better, PET/CT-informed, identification of patients who should proceed to ASCT. The excellent survival of patients in PET/CT-CR indicates that ASCT should remain part of standard therapy for lymphoma.

Sign in / Sign up

Export Citation Format

Share Document